University of Tartu in partnership with Estonian Biocentre and Tallinn Technical University is hosting the Centre of Excellence for Genomics and Translational Medicine
The Centre of Excellence for Genomics and Translational Medicine was awarded funding from EU European Regional Development Fund for the development of CoEs. The funding from EU is 4 818 537 EUR for the period of seven years (2016-2023).
The CoE for Genomics and Translational Medicine (GenTransMed) is based on three research groups from the Estonian Genome Center, University of Tartu and seven research groups from the Faculty of Medicine, University of Tartu. Two research groups are based in the Estonian Biocentre and the Tallinn Technical University.
The objectives of the CoE for Genomics and Translational Medicine
The CoE for Genomics and Translational Medicine stems from the need to translate discoveries in the field of genomics into improved understanding of molecular mechanisms of disease, as well as improved prevention, diagnosis and clinical care. The new interdisciplinary environment of the CoE makes it possible to interpret and rapidly utilize data produced by cutting edge omics technologies. The Centre will explore genetic and biolological mechanisms of disease by 1) investigating DNA sequence variants that contribute to disease through large scale genomic screens, and 2) using molecular and cellular bology techniques complemented by the use of animal models to study their role in disease. This offers an exciting platform for discovering important biological mechanisms that contribute to disease. The outputs of the project are anticipated to unravel processes underlying complex disease, identify new therapeutic targets and enable development of new approaches for disease prevention and precision medicine that will have a major impact in Europe and globally.